Video

Dr. Antonarakis on Sipuleucel-T Plus Radium-223 in Bone-Metastatic CRPC

Emmanuel S. Antonarakis, MBBCh, professor of oncology, Johns Hopkins Medicine, discusses a phase II trial evaluating the combination of sipuleucel-T (Provenge) plus radium-223 dichloride (Xofigo) versus sipuleucel-T alone in patients with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).

Emmanuel S. Antonarakis, MBBCh, professor of oncology, Johns Hopkins Medicine, discusses a phase II trial evaluating the combination of sipuleucel-T (Provenge) plus radium-223 dichloride (Xofigo) versus sipuleucel-T alone in patients with asymptomatic bone-metastatic castration-resistant prostate cancer (mCRPC).

In a phase II study, investigators theorized that radium-223 plus sipuleucel-T would enhance immune response, and lead to an improvement in clinical outcomes in this patient population. Synergy was observed in the combination arm, which was evidenced by prostate-specific antigen (PSA) responses, Antonarakis says. There were 5 confirmed PSA responses (50%) with the combination compared with 0 PSA responses (50%) in the control arm.

Moreover, there was a prolongation of radiographic progression-free survival (PFS) with the combination at 9.3 months versus 3.1 months with sipuleucel-T alone. This was a statistical difference, Antonarakis explains. While the study had limitations and comprised a small number of patients, these data are expected to lead to a larger study evaluating this combination in a broader patient population with longer follow-up, he concludes.

<<< View more from the 2020 Genitourinary Cancers Symposium

Related Videos
Pamela L. Kunz, MD, associate professor, internal medicine (medical oncology), Yale School of Medicine; director, Center for Gastrointestinal (GI) Cancers, chief, GI Medical Oncology, Smilow Cancer Hospital, Yale Cancer Center
Matthew Matasar, MD, chief, Division of Blood Disorders, Rutgers Cancer Institute; professor, medicine, Rutgers Robert Wood Johnson Medical School
Kimberly Cannavale, MPH
Laurence Albigès, MD, PhD
Sattva S. Neelapu, MD
David L. Porter, MD
Suneel Kamath, MD
Craig E. Devoe, MD, MS
Yoshie Umemura, MD, division chief, Neuro-Oncology, William R. and Joan R. Shapiro Chair for Neuro-Oncology Research, associate professor, neurology, Barrow Neurological Institute, chief medical officer, Ivy Brain Tumor Center
Adam M. Burgoyne, MD, PhD, associate clinical professor, medicine, the University of California San Diego